MedTech Venture Builder Collaborative Centre of Excellence

The MedTech Venture Builder (MVB), now in its 2nd year, is a 12-month structured programme in two stages to speed-up the commercial translation of promising medical technologies into robust, investment-ready healthcare ventures.

Supporting companies from across the UK, the MVB, the first of its kind, is a collaborative effort between London’s leading academic institutions, King’s College London (lead), Queen Mary University London, and City & St. George's University London.

Our collaborative focus on MedTech allows us to take ventures a significant step further than what has been achieved before programmatically.

We provide the structures that are critical to de-risking a MedTech company, such as a regulatory plan, a clinical evidence roadmap and stakeholder mapping, extensive hands-on guidance and monthly strategic progress review, all within a fit-for-purpose Quality Management System (QMS).

This is a truly unique opportunity for very select, high-potential MedTech companies from across the UK to receive fully customised, extensive executive support from experts in commercial translation from the partner institutions.

This is only possible with the support of a significant grant by Research England for a Collaborative Centre of Excellence (CCoE) for MedTech translation. The programme is further supported by our strategic partners, Cambridge Consultants.

What we offer

Space at the London Institute for Healthcare Engineering for up to 3 team members per venture, part-time, for the duration of the programme.

Stage 1 (6-month duration): Gearing up

1. Hands-on strategic milestone development
2. Validation of the business case
3. Familiarisation with the rigorous tools, processes and methods of an established MedTech company with industry experts

Stage 2 (6-month duration): Venture Building for investment

1. Deep investment readiness training
2. Development of a regulatory plan with hands-on expert support
3. Access to an ISO13485 Quality Management System, with hands-on support to develop a technical file towards regulatory submission
4. Health technology assessment to generate a robust value proposition for the venture’s offering, with identified stakeholders
5. Generation of a clinical protocol for clinical studies/trials (where applicable and deemed feasible by the Venture Builder experts)
6. Ongoing community support post-programme